Oculus Innovative Sciences Announces Allowance of New Patent in Mexico for
Novel Solution for Use in Invasive Surgical Procedures
*New Regulatory Approvals in Indonesia and Honduras
*New Distribution Partners Added in Finland and Serbia
PETALUMA, Calif., July 2, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences,
Inc. (Nasdaq:OCLS) a global healthcare company that designs, manufactures
andmarkets prescription and non-prescription products in 27 countries, today
announced the allowance of a Mexicanpatent for the use of the company's novel
antimicrobial surgical solutionin the treatment and prevention of
peritonitis. The imminent issuance of this Mexican patent, expiring in 2027,
providesOculus' Latin American partner, More Pharma, the opportunity to
pursue a new drug candidate in Latin America in parallel to Oculus'
subsidiary, Ruthigen, Inc.'s, development of the drug for the U.S. market.The
novel new formulation, RUT58-60, isan advanced next-generation Microcyn
Technology drug candidate specifically engineered for usein invasive surgical
procedures, including peritonitis.
Upon issuance of the patent, Oculus' intellectual property estate (either
owned or licensed to Oculus) will include 36 issued U.S. and international
patents as well 109 pending applications (including U.S. provisional
applications) directed to chemical compositions, apparatuses, methods of
manufacturing and therapeutic uses.
The company's Mexican and Latin American partner, More Pharma, has also
received regulatoryapproval to market the company's Microdacyn60® family of
products in Honduras.Separately, Oculusalso received approval tolauncha
new Microcyn-based medical device in Indonesia. Finally, Oculus added two new
partners in theEuropean Union to sell the Dermacyn® family ofproducts in
Finland and Serbia.
Bruce Thornton, executive vice president of Oculus said: "Our three-pronged
business strategyof adding new products and indications, new partners and new
territories continues to bear fruit as we grow the Microcyn-based product
portfolio in tandem with our international footprint.Now marketed in 27
countries, we are tracking to our target of being commercialized in 30
countries by March 2014. Relative to product portfolio expansion, this
peritonitis patent in Mexico is a solid win for our alliance — allowingour
partner, More Pharma, to pursue this sizable surgical suite opportunity in
Mexico and the Latin American countries—while in parallel, our Ruthigen
subsidiary, targets the U.S. surgical suite with the same RUT58-60 drug
Peritonitis is an inflammation of the peritoneum, the thin tissue that lines
the inner wall of the abdomen and covers most of the abdominal organs.
Peritonitis may be localized or generalized, and may result from infection
(often due to rupture of a hollow organ as may occur in abdominal trauma or
appendicitis) or from a non-infectious process.
About Oculus Innovative Sciences
Oculus Innovative Science is a global healthcare company that designs,
manufactures and marketsprescription and non-prescription products in 27
countries. The company's products are used to treat patients in
surgical/advanced wound management, dermatology, women's health and animal
health markets; addressing the unmet medical needs of these markets, while
raising the standard ofpatient care and lowering overall healthcare costs.
The company's headquarters are in Petaluma, California, with manufacturing
operations in the United States and Latin America. More information can be
Except for historical information herein,matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the commercial and technology progress and futurefinancial performance
of Oculus Innovative Sciences, Inc. and its subsidiaries (the "Company").
These forward-looking statements are identified by the use of words such as
"issuance," "provides," and "tracking," among others. Forward-looking
statements in this press release are subject to certain risks and
uncertainties inherent in the Company's business that could cause actual
results to vary, includingsuchrisks thatregulatory clinical and guideline
developments may change,scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or
approvals,clinical results may not be replicated in actual patient
settings,protection offered bythe Company'spatents and patent applications
may be challenged, invalidated or circumvented by its competitors,the
available market fortheCompany'sproducts will not be as large as
expected,the Company'sproducts will not be able to penetrate one or more
targeted markets,revenues will not be sufficient to fund further development
and clinical studies, the Company may not meet itsfuture capital needs, the
Company may not be able to obtain additional funding, as well as uncertainties
relative to varying product formulations and a multitude of diverse regulatory
and marketing requirements in different countries and municipalities, the
uncertainties associated with an initial public offering of a separate public
company, and the discretion of the Company's Board of Directors to delay or
cancel the spinoff prior to execution, and other risks detailed from time to
time in the Company's filings with the Securities and Exchange Commission
including its annual report on Form 10-K for theyear ended March 31, 2013.
The Company disclaims any obligation to update these forward-looking
statements, except as required by law.
Oculus® and Microcyn® Technology are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service marks are
the property of their respective owners.
CONTACT: Media and Investor Contact:
Oculus Innovative Sciences, Inc.
VP of Public and Investor Relations
Press spacebar to pause and continue. Press esc to stop.